Home » Topics » Disease categories and therapies » Immune

Immune
RSS

VX-148 enters clinical development

Dec. 22, 2000

Treatment of autoimmune diseases with Rituxan

Dec. 20, 2000

Proinflammatory cytokines downregulated by Vasogen's immune modulation therapy

Dec. 19, 2000

EMEA hands down positive opinion for Rapamune

Dec. 12, 2000

Immunosuppressive drug in development at Isotechnika shows promise in phase I

Dec. 11, 2000

Epimmune licenses Valentis technology for vaccine development

Dec. 7, 2000

Phase I study results reported in San Francisco for MEDI-507 in GVHD

Dec. 6, 2000

Phase I safety and pharmacokinetic analysis of AP-1903 reported at Hematology meeting

Dec. 4, 2000

ABX-CBL granted orphan drug status for treatment of acute GVHD

Dec. 4, 2000

Clinical evaluation begins for QS-21-containing flu vaccine

Nov. 28, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 11, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026